IHL-42X
Asset
Combines dronabinol cannabinoid receptor agonism with acetazolamide carbonic anhydrase inhibition to reduce sleep-disordered breathing.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- CNR1
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Obstructive sleep apnea
Phase 2, Recruiting, NCT07635563, clinicaltrials.gov, 15 Oct 2026
In the full profile
- Targets and what it contains5
- Owner and partners1
- Trials1
- Evidence for its targets4
- Competitors6
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.